➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Merck
AstraZeneca
Harvard Business School
Express Scripts

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Chidamide


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Chidamide?

Chidamide is an investigational drug.

There have been 80 clinical trials for Chidamide. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2019.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Sun Yat-sen University, Chipscreen Biosciences, Ltd., and Chinese PLA General Hospital.

There are three US patents protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Chidamide
TitleSponsorPhase
Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLSun Yat-sen UniversityPhase 2
Safety and Efficiency of γ9δ2 T Cell Against Post-transplant Acute Leukemia/Myelodysplastic Syndrome RelapseChinese PLA General HospitalPhase 1/Phase 2
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLCSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3

See all Chidamide clinical trials

Clinical Trial Summary for Chidamide

Top disease conditions for Chidamide
Top clinical trial sponsors for Chidamide

See all Chidamide clinical trials

US Patents for Chidamide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Chidamide   Get Started Free Histone deacetylase inhibitors Orchid Chemicals & Pharmaceuticals Limited (Chennai, IN)   Get Started Free
Chidamide   Get Started Free Crystal form of chidamide, preparation method and use thereof SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (Shenzhen, Guangdong, CN)   Get Started Free
Chidamide   Get Started Free Agents for killing HIV-1-infected cells and application thereof KAGOSHIMA UNIVERSITY (Kogoshima-Shi, Kagoshima, JP)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Chidamide

Drugname Country Document Number Estimated Expiration Related US Patent
Chidamide Australia AU2008309269 1989-12-31   Get Started Free
Chidamide Canada CA2702536 1989-12-31   Get Started Free
Chidamide European Patent Office EP2205563 1989-12-31   Get Started Free
Chidamide Japan JP2011501746 1989-12-31   Get Started Free
Chidamide Japan JP2014144947 1989-12-31   Get Started Free
Chidamide World Intellectual Property Organization (WIPO) WO2009047615 1989-12-31   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
Harvard Business School
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.